MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.

[1]  Kimberly A. Foster,et al.  Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. , 2021, Journal of medicinal chemistry.

[2]  T. Rolph,et al.  Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial , 2021, Nature Medicine.

[3]  Yan Wang,et al.  Clinical significance of small molecule metabolites in the blood of patients with different types of liver injury , 2021, Scientific Reports.

[4]  P. Burra,et al.  NAFLD and liver transplantation: Disease burden, current management and future challenges , 2020, JHEP reports : innovation in hepatology.

[5]  T. Cotter,et al.  Nonalcoholic Steatohepatitis After Liver Transplantation , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  N. Mano,et al.  Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. , 2019, Toxicology and applied pharmacology.

[7]  W. Esler,et al.  Metabolic Targets in Nonalcoholic Fatty Liver Disease , 2019, Cellular and molecular gastroenterology and hepatology.

[8]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  B. Neuschwander‐Tetri,et al.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial , 2018, The Lancet.

[10]  K. Zieniewicz,et al.  2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50‐year evolution of liver transplantation , 2018, Transplant international : official journal of the European Society for Organ Transplantation.

[11]  M. Konerman,et al.  Pharmacotherapy for NASH: Current and emerging. , 2018, Journal of hepatology.

[12]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[13]  M. Suto,et al.  Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[14]  L. Boscá,et al.  Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives , 2017, World journal of gastroenterology.

[15]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[16]  D. Brenner,et al.  Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  S. Dooley,et al.  TGF‐β signalling and liver disease , 2016, The FEBS journal.

[18]  Kazumi Take,et al.  Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization , 2016, PloS one.

[19]  J. Nickels,et al.  MOGAT2: A New Therapeutic Target for Metabolic Syndrome , 2015, Diseases.

[20]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[21]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[22]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[23]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[24]  H. Tornqvist,et al.  Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial , 2014, Diabetes, obesity & metabolism.

[25]  Shirly Pinto,et al.  Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. , 2013, Journal of medicinal chemistry.

[26]  S. Watkins,et al.  Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[27]  Kenji Suzuki,et al.  A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma , 2013, Medical Molecular Morphology.

[28]  C. Tanaka,et al.  An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.

[29]  S. Klein,et al.  Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver[S] , 2012, Journal of Lipid Research.

[30]  Chuanyu Gao,et al.  Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes , 2011, Diabetes Care.

[31]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[32]  Jonathan C. Cohen,et al.  Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.

[33]  Eliot Sugarman,et al.  Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. , 2011, ACS medicinal chemistry letters.

[34]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[35]  Yuguang Shi,et al.  Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.

[36]  Robert V Farese,et al.  Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding , 2009, Nature Medicine.

[37]  C. Chu,et al.  Acylation of Acylglycerols by Acyl Coenzyme A:Diacylglycerol Acyltransferase 1 (DGAT1) , 2008, Journal of Biological Chemistry.

[38]  Michael K. Wendt,et al.  Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. , 2008, Inflammatory bowel diseases.

[39]  J. Hardwick.  Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.

[40]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[41]  M. Bellon,et al.  Free fatty acids have more potent effects on gastric emptying, gut hormones, and appetite than triacylglycerides. , 2007, Gastroenterology.

[42]  S. Chaturvedi,et al.  Oleamide Synthesizing Activity from Rat Kidney , 2007, Journal of Biological Chemistry.

[43]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[44]  Robert V Farese,et al.  The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters Published, JLR Papers in Press, April 16, 2005. DOI 10.1194/jlr.M500036-JLR200 , 2005, Journal of Lipid Research.

[45]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[46]  M. Hochberg.  COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. , 2005, Current topics in medicinal chemistry.

[47]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[48]  Liying Li,et al.  Antifibrogenic role of the cannabinoid receptor CB2 in the liver. , 2005, Gastroenterology.

[49]  Robert V Farese,et al.  MGAT2, a Monoacylglycerol Acyltransferase Expressed in the Small Intestine* , 2003, The Journal of Biological Chemistry.

[50]  J. Lockwood,et al.  Cloning and Functional Characterization of a Mouse Intestinal Acyl-CoA:Monoacylglycerol Acyltransferase, MGAT2* , 2003, The Journal of Biological Chemistry.

[51]  R. Taub,et al.  Identification of Acyl Coenzyme A:Monoacylglycerol Acyltransferase 3, an Intestinal Specific Enzyme Implicated in Dietary Fat Absorption* , 2003, The Journal of Biological Chemistry.

[52]  Xiaodong Wang,et al.  Cytochrome C-mediated apoptosis. , 2003, Annual review of biochemistry.

[53]  L. Petrocellis,et al.  Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. , 2000, Chemistry and physics of lipids.

[54]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[55]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[56]  J. Goldstein,et al.  Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. , 1998, Archives of biochemistry and biophysics.

[57]  N. Thornberry,et al.  A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B , 1997, The Journal of Biological Chemistry.

[58]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[59]  G. Tsujimoto,et al.  Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 , 2005, Nature Medicine.

[60]  R. Mosteller.  Simplified calculation of body-surface area. , 1987, The New England journal of medicine.